Pipeline
Deep and Innovative Pipeline Addressing Immunological Disease
| Product Candidates | Disease Targets | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
|---|---|---|---|---|---|---|
ReproxalapDisease Targets: Dry Eye Disease Type (ophthalmic solution) | Dry Eye Disease | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ReproxalapDisease Targets: Allergic Conjunctivitis Type (ophthalmic solution) | Allergic Conjunctivitis | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-2191Disease Targets: Proliferative Vitreoretinopathy Type (intravitreal injection) | Proliferative Vitreoretinopathy | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-2191Disease Targets: Primary Vitreoretinal Lymphoma Type (intravitreal injection) | Primary Vitreoretinal Lymphoma | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-2191Disease Targets: Retinitis Pigmentosa Type (intravitreal injection) | Retinitis Pigmentosa | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
RASP-Inhibitor Discovery PlatformDisease Targets: Multiple Immune-Mediated Retinal and Systemic Indications | Multiple Immune-Mediated Retinal and Systemic Indications | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-629Disease Targets: Moderate Alcoholic Hepatitis Type (oral administration) | Moderate Alcoholic Hepatitis | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-629Disease Targets: Chronic Cough Type (oral administration) | Chronic Cough | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-629Disease Targets: Sjögren-Larsson Syndrome Type (oral administration) | Sjögren-Larsson Syndrome | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-629Disease Targets: Minimal Change Disease Type (oral administration) | Minimal Change Disease | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |